Overview

A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate change of overactive bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Indonesia Inc.
Treatments:
Solifenacin Succinate